SBLO.F Stock Overview
A contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.82 |
| 52 Week High | JP¥9.82 |
| 52 Week Low | JP¥9.82 |
| Beta | -0.067 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBLO.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.8% |
| 1Y | n/a | -5.5% | 24.6% |
Return vs Industry: Insufficient data to determine how SBLO.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how SBLO.F performed against the US Market.
Price Volatility
| SBLO.F volatility | |
|---|---|
| SBLO.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SBLO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SBLO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,451 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
| SBLO.F fundamental statistics | |
|---|---|
| Market cap | US$445.67m |
| Earnings (TTM) | US$24.72m |
| Revenue (TTM) | US$171.80m |
18.0x
P/E Ratio2.6x
P/S RatioIs SBLO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBLO.F income statement (TTM) | |
|---|---|
| Revenue | JP¥27.07b |
| Cost of Revenue | JP¥12.62b |
| Gross Profit | JP¥14.45b |
| Other Expenses | JP¥10.56b |
| Earnings | JP¥3.90b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 93.58 |
| Gross Margin | 53.38% |
| Net Profit Margin | 14.39% |
| Debt/Equity Ratio | 95.9% |
How did SBLO.F perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield53%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 15:29 |
| End of Day Share Price | 2024/11/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuki Tsukamoto | BofA Global Research |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |